Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 1005-1013

  Jung, Eun Joo ^a   Hur, Minkyu ^a   Kim, Young Lim ^a   Lee, Ge Hyeong ^c   Kim, Jeongmin ^b   Kim, Ikyon ^c   Lee, MinWoo ^b   Han, Ho Kyun ^b   Kim, Mi Soon ^b   Hwang, Sejin ^d   Kim, Sungjoo ^a   Woo, A Mi ^a   Yoon, Yeup ^a   Park, Heon Jin ^e   Won, Jonghwa ^a  

^a Mogam Biotechnology Research Institute   (South Korea)

^b Green Cross Company   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d Hanyang University   (South Korea)

^e Inha University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 2 MERCAPTOIMIDAZOLE; ALBUMIN; CD3 ANTIBODY; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONOMYCIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; 1,4 DIPHENYL 2 MERCAPTOIMIDAZOLE; 1,4-DIPHENYL-2-MERCAPTOIMIDAZOLE; IMMUNOLOGIC FACTOR; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; THIOKETONE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWELLING; T LYMPHOCYTE ACTIVATION; WHITE MATTER; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; HOSPITALIZATION; IMMUNOLOGY; LEUKEMIA CELL LINE; LYMPH NODE; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; SPINAL CORD; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; CELL PROLIFERATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMIDAZOLES; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; JURKAT CELLS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR STRUCTURE; MULTIPLE SCLEROSIS; NFATC TRANSCRIPTION FACTORS; RECEPTORS, ANTIGEN, T-CELL; SEVERITY OF ILLNESS INDEX; SPINAL CORD; T-LYMPHOCYTES; THIONES;

EID: 73349127476     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.154948     Document Type: Article

References (29)

1. Chang MS, Chen BC, Yu MT, Sheu JR, Chen TF, and Lin CH (2005) Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via Ras, Raf-1, ERK, and NF-κB, but not p38 MAPK, pathways. Cell Signal 17:299-310.
2. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, and Hohlfeld R (2000) Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123:508-518.
3. Goverman J, Woods A, Larson L, Weiner LP, Hood L, and Zaller DM (1993) Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72:551-560.
4. Hafler DA (2004) Multiple sclerosis. J Clin Invest 113:788-794.
5. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, and Weiner HL (1986) Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 19:578-587.
6. Kuchroo VK, Martin CA, Greer JM, Ju ST, Sobel RA, and Dorf ME (1993) Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 151:4371-4382.
7. Macián F, López-Rodrí́guez C, and Rao A (2001) Partners in transcription: NFAT and AP-1. Oncogene 20:2476-2489.
8. Macián F (2005) NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5:472-484.
9. McFarland HF and Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913-919.
10. McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, and Miller SD (1992) Induction of active and adoptive chronic-relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 38:229-240.
11. McRae BL, Vanderlugt CL, Dal Canto MC, and Miller SD (1995) Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182:75-85.
12. Olsson T (1995) Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 144:245-268.
13. Raine CS (1984) Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 50:608-635.
14. Rawlings DJ, Sommer K, and Moreno-Garcí́a ME (2006) The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 6:799-812.
15. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, and Ransohoff RM (1997) Management of multiple sclerosis. New Engl J Med 337:1604-1611.
16. Steinman L (2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2:762-764.
17. Strong DM, Ahmed AA, Thurman GB, and Sell KW (1973) In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. J Immunol Methods 2:279-291.
18. Thome M (2008) Multifunctional roles for MALT1 in T-cell activation. Nat Rev Immunol 8:495-500.
19. Traugott U, Reinherz EL, and Raine CS (1983) Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 219:308-310.
20. Tuohy VK, Yu M, Weinstock-Guttman B, and Kinkel RP (1997) Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 99:1682-1690.
21. Tuohy VK, Yu M, Yin L, Kawczak JA, and Kinkel PR (1999a) Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 13:11-20.
22. Tuohy VK, Yu M, Yin L, Kawczak JA, and Kinkel RP (1999b) Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 189:1033-1042.
23. Vanderlugt CL and Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2:85-95.
24. Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, and Miller SD (2000) Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 164:670-678.
25. Winkler M (2000) Cyclosporin as baseline immunosuppression in solid organ transplantation. BioDrugs 14:185-193.
26. Yu M, Johnson JM, and Tuohy VK (1996) A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183:1777-1788.
27. Zamvil S, Nelson P, Trotter J, Mitchell D, Knobler R, Fritz R, and Steinman L (1985a) T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317:355-358.
28. Zamvil SS, Nelson PA, Mitchell DJ, Knobler RL, Fritz RB, and Steinman L (1985b) Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med 162:2107-2124.
29. Zamvil SS and Steinman L (1990) The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8:579-621.